Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — BioStock Global Forum 2026
9 slides from Expres2ion Biotech Holding Ab's conference presentation, May 21, 2026
Slide 1: First-in-Class HER2 Immunotherapy
First - in- Class HER2 Immunotherapy Inducing durable control in HER2 - driven cancers Phase I progress and emergence of value - added data 21 May 2026 Bent U. Frandsen, CEO Hosted by STO: EXPRS2 ExpreS2ion Biotech Holding AB Org. Nr. 559033 - 3729
Slide 2: Investment Case
Investment Case Clinical - stage biotech developing immunotherapies and vaccines Lead Asset Platform Strategic Position ExpreS2 protein manufacturing ES2B - C001 HER2 immunotherapy 34% AdaptVac ownership platform Phase I clinical Phase III validated Clear partnering pathway Why invest now? • First-
Slide 3: The Problem + Solution
The Problem + Solution Current HER2 therapies face resistance and limited durability. ES2B - C001 is designed to induce a broader, multi - epitope immune response with immune memory. Limitations How ES2B - C001 differs Why it matters • Resistance develops • Full HER2 extracellular domain • Immune me
Slide 4: ES2B-C001: Phase I Clinical Update
ES2B - C001: Phase I Clinical Update Updated Phase I plan strengthens the data package while preserving end - 2026 readout timing Trial design and updated plan Early immunogenicity observations • Design: Open - label Phase I dose escalation • Population: Advanced HER2+ or HER2 - low breast cancer 1
Slide 5: ES2B-C001: Enormous Market Value Ahead
ES2B - C001: Enormous Market Value Ahead HER2 therapies already represent multi - billion - Euro commercial markets Global market: HER2 - expressing breast cancer therapies exceeded €17B globally in 2024 1 Estimated addressable opportunity: > €5B Key opportunity: • New immunotherapy approaches & oth
Slide 6: ES2B-C001: Development Strategy
ES2B - C001: Development Strategy Goal: Partnering/Value inflection upon clinical proof of concept — or earlier if signals are strong 2025 2026 2027 2028 2029 Phase I data maturation in 2026 Phase II: Proof of Concept in Breast Cancer • Multiple multi - billion Industry dollar partnership deals prec
Slide 7: Leadership: Fully capable of executing clinical PoC
Leadership: Fully capable of executing clinical PoC Extensive Clinical Development, Oncology & Licensing Experience + 15 FTE colleagues (6 PhDs) Executive + consulting executives Management Bent U. Frandsen, MSc Keith Alexander, MSc Dr. Max M. Soegaard, PhD 200+ years of clinical development and pha
Slide 8: Why Invest Now
Why Invest Now 1️⃣ First- in- class HER 2 immunotherapy 2️⃣ Encouraging immune responses in Phase I 3️⃣ Validated protein platform ( Phase III track record ) 4️⃣ €17B HER 2 oncology market 5️⃣ Clear Phase II licensing strategy 6️⃣ Multiple catalysts over next 12- 18 months Timing and success of futu
Slide 9: Q&A
Q&A NASDAQ FN: EXPRS2 Innovative immunotherapies for a healthier world investor@ expres2ionbio.com https://investor. expres2ionbio.com
ExpreS2ion Biotech Holding — BioStock Global Forum 2026 on 6ix